Chemistry: molecular biology and microbiology – Maintaining blood or sperm in a physiologically active state...
Patent
1996-05-06
1999-03-02
Schwadron, Ronald B.
Chemistry: molecular biology and microbiology
Maintaining blood or sperm in a physiologically active state...
435975, 435343, 4353431, 435334, 436512, 436536, 53038822, 5303887, 53038873, 5303911, 5303913, 530412, 935104, 935108, C07K 1628, C07K 1644, C07K 1600, C12N 520
Patent
active
058769170
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT NZ94/00127, filed Nov. 4, 1994.
FIELD OF THE INVENTION
This invention relates generally to immunological reagents (antibodies) capable of binding to dendritic cells, a method of generating such antibodies and to a process for identifying and purifying dendritic cells from blood using such antibodies.
BACKGROUND OF THE INVENTION
Dendritic cells constitute a distinct group of potent antigen presenting cells (APC) which are bone marrow derived and found as trace populations in the circulation as well as within both lymphoid and nonlymphoid tissues (1-3). Although their importance as the most effective haemopoietic cell involved in the initiation of primary immune responses has been well demonstrated (4-7), no human dendritic cell specific lineage marker has been identified and most features of their ontogeny and relationship to other leukocytes remains unclear.
Phenotypically, human dendritic cells are characterised (1-3,7-11) by a high density of class II MHC antigens, the presence of a wide range of adhesion molecules and the absence or low expression of a range of lineage specific cell surface antigens (CD3, CD14, CD16, CD19, CD57). A number of activation antigens including IRAC (12), HB15 (13), 4F2 (8), IL-2R (7,8), and B7/BB-1 (7,14) have also been reported on human dendritic cells, particularly after activation, although the anti-IRAC and HB15 reagents have not been shown to stain isolated fresh blood dendritic cells. Despite this phenotypic characterisation, identification and therefore purification of dendritic cells remains difficult as the majority of these antigens are expressed by other resting and activated cell types. Many of the functional and phenotypic features of dendritic cells are shared by both Hodgkins cells (HC) and Hodgkins Disease (HD) derived cell lines and there is increasing evidence to support the hypothesis, that in some instances, HC represent a malignant form of dendritic cell (15-17).
It is therefore an object of the present invention to inter alia provide a method of generating immunological reagents for use in a process for identifying and purifying dendritic cells.
Previous attempts to isolate antibodies specific for human dendritic cells have been largely unsuccessful. A number of these attempts have been directed toward monoclonal antibodies and have utilised an improved dendritic cell purification method to prepare immunogens (32) and a rapid two-colour flow cytometric screening procedure that allows large numbers of hybridoma supernatants to be examined in each fusion (33). These attempts failed, yielding only hybridomas that bind common antigens of both dendritic cells and other leukocytes.
Further attempts to generate dendritic cell-specific antibodies, in this case, through tolerisation of the host prior to immunisation with dendritic cells, have been reported (34). Two methods of tolerisation are compared. The first method involves the administration of a cytotoxic antiproliferative agent (cyclophosphamide(CP)) in conjunction with immunodominant leukocyte antigens to preferentially kill B cells that respond to unwanted epitopes. In the second method, tolerisation is induced by injecting the undesired immunodominant leukocyte antigens during the neonatal period.
It is reported that the first method generates only non-specific immunosuppression whereas the second method potentially leads to a state of antigen-specific non-responsiveness. However, the ability of the tolerised host to generate antibodies specific for dendritic cells is not demonstrated nor is any data provided regarding the efficiency of the method in producing a positive serological response to dendritic cells. All that is shown is tolerisation ie. lack of reactivity with T blasts.
The applicant's own investigations have however found that, in practice, an approach involving tolerisation of a neonate host with available immunodominant leukocyte antigens is not generally effective in raising immunologically useful antibodies against dendritic cells. In particular,
REFERENCES:
B.Hock et al. Tissue Antigens, vol. 42 No. 4, Oct. 1993, p. 241.
J. McKenzie et al. Immunology, vol. 77 No. 3, Nov. 1992, pp. 345-353.
Canterbury Health Limited
Schwadron Ronald B.
LandOfFree
Dendritic cell-specific antibodies and method for their preparat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dendritic cell-specific antibodies and method for their preparat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dendritic cell-specific antibodies and method for their preparat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-421252